Monthly, Peer-Reviewed, Refereed, Indexed Journal

STRESS DEGRADATION STUDIES FOR SIMULTANEOUS ESTIMATION OF RESVERATROL AND GALLIC ACID BY RP-HPLC

¹AMANDEEP KAUR*, ²MONIKA GUPTA

¹Department of Pharmaceutical Chemistry, A.S.B.A.S.J.S.M. College of Pharmacy, Bela (Ropar)-140111 Pb. Email: amandeepsaini7240@gmail.com

²HOD of Pharmaceutical Chemistry, A.S.B.A.S.J.S.M. College of Pharmacy, Bela (Ropar)-140111 Pb.

Email: monikaguptaa@gmail.com

Abstract: A stability indicating reversed- phase HPLC method has been developed for simultaneous estimation of gallic acid and resveratrol. The proposed RP-HPLC method utilizes a Nucleodur C_{18} having dimensions 5μ (250×4.6 mm) column, mobile phase consisting of Phosphate buffer pH 3 ±0.02 pH adjusted with ortho phosphoric acid and methanol and acetonitrile in the proportion of 50: 30: 20 v/v and UV detection at 263 nm and 301 nm for gallic acid and resveratrol, respectively using a shimadzu SPD-10AVP UV-Visible detector. Gallic acid and Resveratrol were exposed to acidic, basic, thermal, photolytic and oxidative stress conditions and stressed samples were analysed by the proposed method.

Keywords: Resveratrol, Gallic acid, Forced degradation study, stress testing.

1. INTRODUCTION:

Resveratrol (3,5,4'-trihydroxy-*trans*-stilbene) is a stilbenoid (Fig. 1.1) [1]. It is white powder with slight yellow cast, practically very slightly in water, but soluble in organic solvents such as methanol, acetone, DMSO, acetonitrile etc. It has molecular formula $C_{14}H_{12}O_3$ and molecular weight 228.25 with a melting point of 261 to 263 °C. It has intracellular antioxidant activity [2] and activates SIRT1, a NAD⁺-dependent histone deacetylase involved in mitochondrial biogenesis and the enhancement of peroxisome proliferator- γ -activated receptor coactivator- 1α (PGC- 1α) and FOXO activity [9-10]. The anti-diabetic, neuroprotective and anti-adipogenic actions of resveratrol may be mediated via SIRT1activation [7-8].

Gallic acid (also known as 3,4,5-trihydroxybenzoic acid) is a trihydroxybenzoic acid, a type of phenolic acid (Fig. 1.2) [3]. It is white, yellowish-white, or pale fawn- colored crystals, soluble in alcohol, ether, glycerol, acetone negligible in benzene, chloroform, petroleum ether [11]. It has molecular formula of $C_7H_6O_5$ and molecular weight 170.12 with a melting point of 260 °C. Gallic acid is a water soluble phenolic acid present in grapes and in the leaves of many plants [4]. Gallic acid esters, such as tannins, catechin gallates and aliphatic gallates are potent antioxidants in vitro [5]. However, gallic acid itself also appears to have antioxidant, anticarcinogenic and antiangiogenic activity in vitro [6].

Fig. 1.1: Chemical structure of Resveratrol

Fig. 1.2: Chemical structure of Gallic acid

Literature survey revealed that there is no method has been reported or published that is extensively focused on stress stability studies for simultaneous estimation of the gallic acid and resveratrol. Therefore, the aim of the present work is to establish the inherent stability of gallic acid and resveratrol through forced degradation studies. Aim of stability testing is to prove how the quality of a drug substance or drug product changes with time under the influence of a variety of factors such as excipients, temperature, pH, oxygen, light etc. Thus, stress studies are required in order to generate the method development, and its validation.

ISSN: 2456-6683 Impact Factor: 4.526 Volume - 2, Issue - 11, Nov - 2018
Publication Date: 30/11/2018

2. MATERIAL AND METHOD:

The drug Resveratrol (RES) was gifted from Lupin laboratories [Aurangabad, Bihar] and Gallic acid was procured as a gift sample from Symbiosis pharmaceuticals private limited [Sirmor, H.P.]. Acetonitrile [HPLC grade] and triethylamine were procured from Thermo fisher scientific india private limited [Mumbai] and glacial acetic acid purchased from Fischer scientific [Mumbai]. Orthophosphoric acid was procured from Thermo fisher scientific india private limited [Mumbai], hydrochloric acid (Merck, India), sodium hydroxide (Loba Chem, Mumbai) and hydrogen peroxide (Loba Chem, Mumbai) were used for analytical purposes.

2.1 HPLC Instrumentation and Chromatographic Parameters:

The chromatographic system used for the investigation was on shimadzu LC-2010 ATVP prominence liquid chromatograph and using shimadzu SPD-10AVP UV-Visible detector composed of binary pump, degasser, auto injector, and column oven. The chromatographic analysis was performed on a Nucleodur C_{18} having dimensions 5μ (250×4.6 mm) column. The mobile phase was a consisting of Phosphate buffer pH 3 ±0.02, pH adjusted with ortho phosphoric acid and methanol and acetonitrile (50: 30: 20 v/v), pumped at a flow rate of 1mL/min. The column temperature was maintained at 40°C, and the detection wavelength were 306 nm and 263 nm for Resveratrol and Gallic acid, respectively. Measurements were made with injection volume 20 μ L and the run time was 7 min for each injection of stressed sample.

2.2 Preparation of buffer solution:

The buffer solution was prepared by dissolving 7.0g of potassium di hydrogen ortho phosphate in 1000ml of HPLC grade water and pH 3.0 was adjusted with orthophosphoric acid. It was filtered through $0.45\mu m$ nylon membrane filter and degassed with sonicator.

2.3 Preparation of blank solution:

Acetonitrile and methanol in ratio of 50: 50 was used as blank solution.

2.4 Preparation of standard solution:

The quantity of powder equivalent to 10 mg of resveratrol and gallic acid were weighed and transferred into 10 ml volumetric flask, 5 ml of diluent was added and sonicated for 15 minutes and the volume was made upto the mark with diluent. From this further dilution was made to get the final concentrations of resveratrol and gallic acid.

2.5 Stress degradation studies of Gallic acid and Resveratrol:

Intentional degradation was attempted to stress conditions of UV degradation, photolytic degradation, acid hydrolysis (using HCl), base hydrolysis (using NaOH) and oxidative degradation (using H2O2). Drug concentration of 1 mg/ml was used in all the degradation studies. After completion of the degradation processes, the solutions were neutralized and diluted with mobile phase.

2.5.1 Acid hydrolysis:

Sample solution containing 1 ml aliquot of mixture of both drugs was transferred into a 10 ml of amber volumetric flask, then mixed with 1 ml of 0.1M HCl and left to stand for 1 hr, 2 hr, 4 hr at $60^{\circ}\text{C} \pm 2^{\circ}\text{C}$ after heating on bath samples were neutralized with 1 ml 0.1M NaOH and diluted up to 10 ml with diluents, sonicated and filtered through 0.22 μ m membrane filter paper and injected in to HPLC system. All determinations were conducted in triplicate

2.5.2 Basic hydrolysis:

Sample solution containing 1 ml aliquot of mixtures of both drugs was transferred into a 10 ml of amber volumetric flask, then mixed with 1 ml of 0.1M NaOH and left to stand for 1 hr, 2 hr, 4 hr at 60° C \pm 2°C after heating on bath samples were neutralized with 1 ml 0.1M HCl and diluted up to 10 ml with diluents, sonicated and filtered through 0.22 μ m membrane filter paper and injected into HPLC system. All determinations were conducted in triplicate.

2.5.3 Oxidative degradation:

Sample solution containing 1 ml aliquot of mixture of both drugs was transferred into a 10 ml amber volumetric flask, then mixed with 1 ml of 1% (v/v) hydrogen peroxide and left to stand for 1 hr, 2 hr and 4 hr at 60 °C \pm 2°C after heating on bath samples were diluted up to 10 ml with mobile phase. All three solutions were injected in triplicate.

2.5.4 Thermal degradation:

One milliliter aliquot of a sample solution containing mixture of both drugs was transferred to a 10 ml amber volumetric flask and then heated for 1 hr, 2 hr and 4 hr at 60 $^{\circ}$ C \pm 2 $^{\circ}$ C. The resultant each of solution were diluted in mobile phase up to 10 ml and injected in triplicate.

2.5.5 UV degradation:

Photolytic degradation was studied by placing a mixture of both solution in a clear volumetric flask and exposing it to direct UV light (254nm) for 1 hr, 2 hr and 4 hr. The resultant solution was injected in triplicate.

3. RESULTS AND DISCUSSION:

3.1 Degradation in Acid:

The chromatogram for acid degradation of gallic acid dose not showed any significant degradation or additional peak of sample after 1 hr, 2 hr and 4 hr at 60 °C \pm 2 °C degradation study (Figure 3.1). Resveratrol gradually decreased with time.

Table 3.1: Acid degradation of Gallic acid

Conditions	Conditions Conc.		Time Peak area		Mo	ean	% Degradation
Conditions	(μg/ml)	period	Before	After	Before	After	76 Degradation
			188216	179259	187615.7	184421	1.7027718
	5	1 hr	184653	185212	18/013./	104421	1.7027716
			189978	188792			
Acid			188216	184218	1076157	1942067	1 71574150
degradation	5	2 hr	184653	184516	187615.7	184396.7	1.71574158
degradation			189978	184456			
			188216	182408	1076157	182307.7	2.82918804
	5	4 hr	184653	182320	187615.7	182307.7	2.82918804
			189978	182195			

Table 3.2: Acid degradation of Resveratrol

Conditions	Conc.	Time	Peak area		M	lean	% Degradation
Conditions	(µg/ml)	period	Before	After	Before	After	70 Degradation
			731859	53231	732355	36481.33	95.0186271
	5	1 hr	731831	33897	,6266	50.01.65	y0.0100 2 /1
			733375	22316			
Acid			731859	17444	732355	17134.33	97.6603787
degradation	5	2 hr	731831	16567	132333	1/134.33	97.0003787
			733375	17392			
			731859	7344	732355	7270.667	99.007221
	5	4 hr	731831	7144	134333	1210.001	77.007221
			733375	7324			




Fig. 3.1: Acid degradation

3.2. Degradation in Alkali:

The chromatogram for base degradation of Gallic acid do not showed any significant degradation of sample after 1 hr, 2 hr and 4 hr at 60 °C \pm 2 °C degradation study but Resveratrol shows significant degradation after 1 hr, 2 hr and 4 hr at 60 °C \pm 2 °C degradation study. (Figure 3.2)

Table 3.3: Base degradation of Gallic acid

Conditions	Conc.	Time	Peak	area	M	ean	%
Conditions	(μg/ml)	period	Before	After	Before	After	Degradation
			188216	185198	1076157	1051507	1 21205616
	5	1 hr	184653	185256	187615.7	185150.7	1.31385616
			189978	184998			
Dania			188216	183965	1076157	192605	2.09072200
Basic	5	2 hr	184653	183512	187615.7	183695	2.08973309
degradation			189978	183608			
			188216	181981	1076157	101775	2 11210170
	5	4 hr	184653	181625	187615.7	181775	3.11310178
			189978	181719			

Table 3.4: Base degradation of Resveratrol

Table 5.4: Base degradation of Resveratroi									
Conditions	Conc.	Time	Peak a	area	Mean		0/ Dogwodotion		
Conditions	(µg/ml)	period	Before	After	Before	After	% Degradation		
			731859	57680	732355	57662 67	92.1262685		
	5	1 hr	731831	57562	132333	57663.67	92.1202083		
			733375	57749					
D ' -			731859	55584	722255	55(12	02.4062704		
Basic	5	2 hr	731831	55960	732355	55613	92.4062784		
degradation			733375	55295					
			731859	43005	722255	42451 67	04.0669574		
	5	4 hr	731831	43045	732355	43451.67	94.0668574		
			733375	44305					




Fig. 3.2: Base degradation

3.3 Oxidative Stress:

The chromatogram for oxidative degradation of both drugs showed significant degradation in area, symmetry and additional peaks after 1 hr, 2 hr and 4 hr at 60 $^{\circ}$ C \pm 2 $^{\circ}$ C of oxidative degradation study (Figure 3.3).

Table 3.5: Oxidative degradation of Gallic acid

Tuble 5.5. Oxidative degradation of Gaine dela										
Canditions	Conc.	Time	Peak a	area	I	Mean	0/ Dooredation			
Conditions	(µg/ml)	period	Before	After	Before	After	% Degradation			
	_		188216	39692	187615.7	39451.33	78.9722607			
Oxidative	5	1 hr	184653	39850	10,010.,	57 10 1.55	70.5722007			
Degradation			189978	38812						
	5	2 hr	188216	37628	187615.7	37072.33	80.2402784			

Impact Factor: 4.526	Publication Date: 30

		184653	37047			
		189978	36542			
		188216	32282	1076157	21745 22	92.0705026
5	4 hr	184653	31729	187615.7	31745.33	83.0795936
		189978	31225]		

Table 3.6: Oxidative degradation of Resveratrol

		1 4010 010	· OMuuli it ut	8		V-	
Conditions	Conc.	Time	Peak	area	Mean		% Degradation
Conditions	(μg/ml)	period	Before	After	Before	After	% Degradation
			731859	221573	732355	215553	
	5	1 hr	731831	214794	702000		70.567143
			733375	210292			
Oxidative			731859	123607	732355	120844.7	83.4991682
degradation	5	2 hr	731831	120510	132333		
\mathcal{E}			733375	118417			
			731859	5340	732355	5115 667	00 2564171
	5	4 hr	731831	5512	132333	5445.667	99.2564171
			733375	5485			




Fig. 3.3: Oxidative degradation

3.4 Thermal Stress:

The chromatogram for thermal degradation of Gallic acid do not showed any significant degradation or additional peak of sample after 1 hr, 2 hr and 4 hr at 60 °C \pm 2 °C degradation study but Resveratrol shows significant degradation after 1 hr, 2 hr and 4 hr at 60 °C \pm 2 °C degradation study. (Figure 3.4)

Table 3.7: Thermal degradation of Gallic acid

Conditions	Conc.	Time	Peak a	area	N.	I ean	% Degradation
Conditions	(μg/ml)	period	Before	After	Before	After	76 Degradation
	_		188216	187601	187615.7	187600.7	0.00799507
	5	1 hr	184653	187425	10,0101,	10,000,	0.007,5507
			189978	187776			
Thermal			188216	185002	187615.7	185215.3	1.27938854
Degradation	5	2 hr	184653	185212	16/013./	165215.5	1.27930034
			189978	185432			
			188216	183639	187615.7	183082.3	2.4162872
	5	4 hr	184653	182408	16/013./	163062.3	2.4102672
			189978	183200			

Table 3.8: Thermal degradation of Resveratrol

Conditions	Conc.	Time Peak area				Mean	% Degradation
Conditions	(μg/ml)	period	Before	After	Before	After	% Degradation
	_		731859	376192	732355	376240.3	48.6259624
	5	1 hr	731831	376531	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
			733375	375998			
TD1 1			731859	285018	732355	285087.3	61.0725218
Thermal	5	2 hr	731831	285315	132333	263067.3	01.0723216
degradation			733375	284929			
	_	4.1	731859	217139	732355	217374	70.3184931
	5	4 hr	731831	217591			
			733375	217392			




Fig. 3.4: Thermal degradation

3.5 UV degradation:

The chromatogram for UV degradation of Gallic acid do not showed any significant degradation or additional peak of sample after 1 hr, 2 hr and 4 hr at 60 °C \pm 2 °C degradation study but Resveratrol shows significant degradation after 1 hr, 2 hr and 4 hr at 60 °C \pm 2 °C degradation study. (Figure 3.5)

Table 3.9: UV degradation of Gallic acid

		Tabl	e 3.3. U v deg	l auauon oi	Game acid		
Conditions	Conc.	Time	Peak :	area	I I	Mean	0/ Degradation
Conditions	(µg/ml)	period	Before	After	Before	After	% Degradation
			188216	184912	187615.7	184369.7	1.7301327
	5	1 hr	184653	184198	10/015.7	104309.7	1.7301327
			189978	183999			
1117			188216	182468			
UV	5	2 hr	184653	182191	187615.7	182406.3	2.77659826
degradation	3	2 nr	189978	182560			
			188216	180108	107615.7	100200.2	2.00406995
	5	4 hr	184653	180512	187615.7	180289.3	3.90496885
			189978	180248			

Table 3.10: UV degradation of Resveratrol

		I unic t	C , acg.	uddioii oi i	es i el aci oi		
Conditions	Conditions Conc. Time		Peak a	Peak area		Mean	0/ Degradation
Conditions	(μg/ml)	period	Before	After	Before	After	% Degradation
UV	_		731859	384031	732355	385666.7	47.3388361
degradation	5	1 hr	731831	386706	,02000	20200011	1,1000001
<i>5</i>			733375	386263			

Monthly, Peer-Reviewed, Refereed, Indexed Journal Impact Factor: 4.526

			1			
		731859	284028	732355	284109	61.2061091
5	2 hr	731831	284062	132333	204109	01.2001091
		733375	284237			
		731859	217139	732355	216852.3	70.3897245
5	4 hr	731831	216705	132333	210052.5	70.3897243
		733375	216713			




Fig. 3.5: UV degradation

4. CONCLUSION:

Forced degradation studies revealed that reveratrol prone to degraded under all the performed conditions. Moreover, the content of degradation of gallic acid and resveratrol in various conditions, such as alkaline, acidic, oxidation, thermal and photolytic, were observed and quantitatively analyzed by this HPLC method. The information, thus, obtained will facilitate pharmaceutical development in areas such as formulation development, manufacturing, and packaging, where knowledge of chemical behavior can be used to improve the quality of drug product.

5. ACKNOWLEDGMENT:

I would like to acknowledge ASBASJSM College of Pharmacy, Bela(Ropar) for his support and help to maintain balanced circumstances during project work. And I would like to acknowledge Oniosome Pvt. Ltd. Mohali, for providing the facilities for this research work.

REFERENCES:

- 1. Figueiras TS, Petersen MTN, Petersen SB. Activation energy of light induced isomerization of resveratrol. J. Fluoresc, 2011; 21: 1897–1906.
- 2. Ortuno J, Covas MI, Farre M. Matrix effects on the bioavailability of resveratrol in humans. Food Chemistry, 2010; 120: 1123–1130.
- 3. Singh G, Roopa SP, Pandit V. Development and validation of a HPLC method for the determination of transresveratrol in spiked human plasma. J. Adv. Pharm. Tech. Res, 2016; 3: 130-135.
- 4. Kumar S, Lather V, Pandita D. Stability indicating simplified HPLC method for simultaneous analysis of resveratrol and quercetin in nanoparticles amd human plasma. Food Chemistry, 2016; 197: 959-964.
- 5. Urbaniaka A, Delgado M, Kacprzak K, Chambers TC. Activity of Resveratrol trimesters against primary acute lymphoblastic leukemia cells. Bioorganic & Medicinal Chemistry Letters, 2017; 27: 2766-2770.
- 6. Cvetkovic ZS, Nikolic VD, Savic IM, Nikolic LB. Development and validation of an RP-HPLC method for quantification of trans-resveratrol in the plant extracts. Hem. Ind, 2015; 69: 679–687.
- 7. Kubo I, Masuoka N, Joung T. Multifunctional Antioxidant Activities of Alkyl Gallates. The Open Bioactive Compounds Journal, 2010; 3: 1-11.
- 8. Damle M, Dalavi N. Development and Validation of Stability Indicating HPLC Method for Determination of Ellagic and Gallic acid in Jambul Seeds (Syzygium Cumini). Int J Appl Sci Biotechnol, 2015; 3: 434-438.
- 9. Samee W, Vorarat S. Simultaneous Determination of Gallic acid, Catechin, Rutin, Ellagic Acid and Quercetin in Flower Extracts of Michelia alba, Caesalpinia pulcherrima and Nelumbo nuciferaby HPLC. Thai Pharm Health Sci J, 2007; 2(2): 131-137.
- 10. Badhani B, Sharma N, Kakkar R. Gallic acid: a versatile antioxidant with promising therapeutic and industrial applications. RSC Adv, 2015; 5: 27540-27557.
- 11. Verma S, Singh A, Mishra A. Gallic acid: Molecular rival of cancer. Enviornmental Toxicology and Pharmacology, 2013; 35: 473-485.